Baird Initiates Coverage On Regenxbio with Outperform Rating, Announces Price Target of $42
Portfolio Pulse from richadhand@benzinga.com
Baird analyst Brian Skorney initiates coverage on Regenxbio (NASDAQ:RGNX) with an Outperform rating and announces a price target of $42.
June 20, 2023 | 12:44 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Regenxbio (NASDAQ:RGNX) receives an Outperform rating and a price target of $42 from Baird analyst Brian Skorney.
The Outperform rating and price target of $42 announced by Baird analyst Brian Skorney indicate a positive outlook for Regenxbio's stock in the short term. This news is highly relevant and important for investors in RGNX, as it suggests potential growth and an upward price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100